Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 31 July 2025 to 6 August 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 31 July 2025 to 6 August 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 41 189 shares. The table below ...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 31 juli 2025 tot 6 augustus 2025 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 31 juli 2025 tot 6 augustus 2025, Kepler Cheuvreux...
ONWARD Medical gibt Ernennung von Lucas Buchanan als Vorstandsmitglied bekannt Buchanan ist ehemaliger CFO und COO von Silk Road Medical, wo er erfolgreich ein Medizintechnikunternehmen in der Wachstumsphase skalierte, das schließlich von Boston Scientific übernommen wurde.Buchanan, früher Risikokapitalgeber bei der Vertical Group, ist außerdem aktiver Investor, Berater und Vorstandsmitglied mehrerer innovativer Medizintechnikunternehmen und Gesundheitsinvestitionsfonds. EINDHOVEN, Niederlande, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD und US OTCQX: ONWRY), da...
ONWARD Medical annonce la nomination de Lucas Buchanan à son conseil d’administration M. Buchanan est l’ancien directeur financier et directeur des opérations de Silk Road Medical, où il a développé avec succès une entreprise de dispositifs médicaux en phase de croissance, aboutissant à son acquisition par Boston Scientific.Ancien investisseur en capital-risque chez Vertical Group, M. Buchanan est également un investisseur actif, conseiller et membre du conseil d’administration de plusieurs entreprises innovantes dans le domaine des dispositifs médicaux et de fonds d’investissement dans le ...
We zoom in on the deal announced between HOMI and City Forward. HOMI will redevelop 8 offices into 700-750 apartments over the next 7-9 years. The deal will push the residential portfolio of HOMI over EUR 1.2B. We assume a total investment of EUR 280.0m, 20% development margin and EUR 14.0m gross rental income. We are very supportive of this deal but the gains on the development are back-end loaded while we see a short term headwind in a building right expiry in Louvain La Neuve (10.9% rents). ...
ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific. Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and healthcare investment funds. EINDHOVEN, The Netherlands, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurote...
Belgian telcos: Telenet small positive net adds, good financials, guidance up. Kinepolis: US Cinemark strong, 5% growth in US tickets, consumption per visitor. KPN: VodafoneZiggo 2Q25 very weak, guidance maintained. PostNL: 2Q25 beats underlying slightly; FY25 guidance reiterated, EU court appeal
Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...
Bekaert - Update on the Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 24 July 2025 to 30 July 2025 Liquidity agreement In relation to the renewed liquidity agreement with Kepler Cheuvreux announced on , Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 6 400 shares during the period from 24 July 2025 to 30 July 2025 on Euronext Brussels. During the same period, Kepler Cheuvreux on behalf of Bekaert has sold 1 600 shares on Euronext Brussels. The tables below provide an overview of the transactions under t...
Bekaert - Update over de Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 24 juli 2025 tot 30 juli 2025 Liquiditeitsovereenkomst In het kader van het hernieuwde liquiditeitscontract met Kepler Cheuvreux aangekondigd op , maakt Bekaert vandaag bekend dat Kepler Cheuvreux namens Bekaert 6 400 aandelen heeft aangekocht in de periode van 24 juli 2025 tot 30 juli 2025 op Euronext Brussels. Tijdens dezelfde periode heeft Kepler Cheuvreux namens Bekaert 1 600 aandelen verkocht op Euronext Brussels. De onderstaande tab...
AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...
1H uEBIT declined by 16% which was in line with our forecast and 4% below consensus. Bekaert lowered FY25 uEBIT margin guidance from flat (8.8%) to an 8.0-8.5% range and we reduced our FY25 uEBIT forecast by 6%. The gradually improving portfolio profile, compelling valuation (EV/EBITDA25E of c. 4x), solid FCF generation and ongoing support from the € 200m SBB program prompt us to maintain our BUY rating and € 55 TP.
Bekaert - Update on the Share Buyback Program Bekaert announces the next tranche of its Share Buyback Program Bekaert announces that it will start the next tranche of its buyback program on 31 July 2025, for a total consideration of up to € 25 million. It is intended that, subject to market conditions, this tranche will be completed prior to the release of the Q3 trading update, scheduled for 21 November 2025. During this period, Bekaert will regularly publish press releases with updates on the progress made, as required by law. This information will also be available on the of our websi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.